TABLE 1.
Susceptibility profiles of 638 ESBL-producing E. coli isolates, interpreted using 2010 and 2014 CLSI breakpoints
| Drug | No. (%) with CLSI interpretation of: |
||
|---|---|---|---|
| Sensitive | Intermediate | Resistant | |
| Aztreonam | 69 (10.8) | 53 (8.3) | 516 (80.9) |
| Cefotaxime | 0 (0) | 14 (2.2) | 624 (97.8) |
| Ceftazidime | 141 (22.1) | 62 (9.7) | 435 (68.2) |
| Ceftriaxone | 18 (2.8) | 4 (0.6) | 616 (96.6) |
| Cefuroxime | 23 (3.6) | 7 (1.1) | 608 (95.3) |
| Cefepime | |||
| 2010 breakpoints | 126 (19.7) | 51 (8.0) | 461 (72.3) |
| 2014 breakpoints | 126 (19.7)a | 512 (80.3) | |
a
Sensitive or sensitive dose dependent.